Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Vemurafenib

FDA-approved product (tablet, oral), marketed as Zelboraf.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Vemurafenib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Cutaneous melanoma
  • Melanoma
  • Metastatic melanoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
B-raf serine-threonine kinase (braf) inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA65.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli41.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Vemurafenib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-9.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Vemurafenib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU])

    NCT03139513 · start 2016-10-27

    Registered record
    Registry ID
    NCT03139513
    Conditions
    Melanoma
    Interventions
    Cobimetinib; Vemurafenib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2016-10-27
    Completion
    2018-08-22
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma
    InterventionCobimetinib; Vemurafenib
    PhaseNot recorded
    Registry statusCompleted

  • Prevention of Phototoxicities in Patients Undergoing Vemurafenib Treatment

    NCT03108209 · start 2016-07

    Registered record
    Registry ID
    NCT03108209
    Conditions
    Phototoxicity
    Interventions
    Photoderm Max lait SPF50+; Photoderm Max Stick SPF50+
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-07
    Completion
    2018-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPhototoxicity
    InterventionPhotoderm Max lait SPF50+; Photoderm Max Stick SPF50+
    PhaseNot applicable
    Registry statusCompleted

  • A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma

    NCT02768207 · start 2016-05-23

    Registered record
    Registry ID
    NCT02768207
    Conditions
    Metastatic Melanoma
    Interventions
    Cobimetinib; Vemurafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-05-23
    Completion
    2019-06-27
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Melanoma
    InterventionCobimetinib; Vemurafenib
    PhasePhase 2
    Registry statusCompleted

  • A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib

    NCT02382549 · start 2016-04

    Registered record
    Registry ID
    NCT02382549
    Conditions
    Melanoma
    Interventions
    BRAF inhibitor; 6MHP; MEK inhibitor
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Terminated
    Start
    2016-04
    Completion
    2022-02-28
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma
    InterventionBRAF inhibitor; 6MHP; MEK inhibitor
    PhaseEarly phase 1
    Registry statusTerminated

  • Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases

    NCT02036086 · start 2015-08

    Registered record
    Registry ID
    NCT02036086
    Conditions
    Melanoma
    Interventions
    Vemurafenib; Cobimetinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2015-08
    Completion
    2024-01-31
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma
    InterventionVemurafenib; Cobimetinib
    PhasePhase 2
    Registry statusUnknown

  • Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379

    NCT02456701 · start 2015-06

    Registered record
    Registry ID
    NCT02456701
    Conditions
    Thyroid Cancer
    Interventions
    KTN3379; vemurafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-06
    Completion
    2016-10-13
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThyroid Cancer
    InterventionKTN3379; vemurafenib
    PhasePhase 1
    Registry statusCompleted

  • Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases

    NCT02230306 · start 2015-02

    Registered record
    Registry ID
    NCT02230306
    Conditions
    Active Melanoma Brain Metastases
    Interventions
    Cobimetinib; Vemurafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2015-02
    Completion
    2016-03
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionActive Melanoma Brain Metastases
    InterventionCobimetinib; Vemurafenib
    PhasePhase 2
    Registry statusTerminated

  • Vemurafenib and TIL Therapy for Metastatic Melanoma

    NCT02354690 · start 2014-11

    Registered record
    Registry ID
    NCT02354690
    Conditions
    Metastatic Melanoma
    Interventions
    Vemurafenib; Lymphodepleting chemotherapy; TIL infusion; Interleukin-2
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2014-11
    Completion
    2018-12-31
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Melanoma
    InterventionVemurafenib; Lymphodepleting chemotherapy; TIL infusion; Interleukin-2
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors

    NCT03176485 · start 2014-10-17

    Registered record
    Registry ID
    NCT03176485
    Conditions
    Metastatic Cancer; Melanoma; Colon Cancer; Differentiated Thyroid Cancer; Hepatocellular Carcinoma; Renal Cell Carcinoma; Metastatic Melanoma; HCC; Metastatic Colon Cancer
    Interventions
    Solar Simulator
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2014-10-17
    Completion
    2018-11-01
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Cancer; Melanoma; Colon Cancer; Differentiated Thyroid Cancer +5 more
    InterventionSolar Simulator
    PhaseNot applicable
    Registry statusCompleted

  • A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered Vemurafenib

    NCT02115035 · start 2014-07

    Registered record
    Registry ID
    NCT02115035
    Conditions
    Multiple Myeloma
    Interventions
    Vermurafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Withdrawn
    Start
    2014-07
    Completion
    2017-07
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionVermurafenib
    PhasePhase 1 / Phase 2
    Registry statusWithdrawn

  • N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy

    NCT02142036 · start 2014-05

    Registered record
    Registry ID
    NCT02142036
    Conditions
    Metastatic Cancer
    Interventions
    EMA-approved ATI based targeted therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-05
    Completion
    2018-08
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Cancer
    InterventionEMA-approved ATI based targeted therapy
    PhasePhase 2
    Registry statusCompleted

  • A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma

    NCT02068079 · start 2014-04

    Registered record
    Registry ID
    NCT02068079
    Conditions
    Melanoma
    Interventions
    Vemurafenib and Trientine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2014-04
    Completion
    2015-11
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma
    InterventionVemurafenib and Trientine
    PhasePhase 1
    Registry statusWithdrawn

  • Vaccination With Peptides in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Unresectable Stage III or IV Malignant Melanoma

    NCT02077114 · start 2014-02

    Registered record
    Registry ID
    NCT02077114
    Conditions
    Malignant Melanoma With Metastasis
    Interventions
    Vaccine consisting of a peptide derived from the protein IDO
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-02
    Completion
    Not recorded
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Melanoma With Metastasis
    InterventionVaccine consisting of a peptide derived from the protein IDO
    PhasePhase 1
    Registry statusCompleted

  • Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study

    NCT02052193 · start 2014-01

    Registered record
    Registry ID
    NCT02052193
    Conditions
    Metastatic Melanoma (Carrying BRAF V600 Mutation)
    Interventions
    Dabrafenib; Vemurafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2014-01
    Completion
    2014-12-15
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Melanoma (Carrying BRAF V600 Mutation)
    InterventionDabrafenib; Vemurafenib
    PhasePhase 2
    Registry statusTerminated

  • A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma

    NCT02050321 · start 2013-12

    Registered record
    Registry ID
    NCT02050321
    Conditions
    Malignant Melanoma
    Interventions
    Acitretin; Vemurafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2013-12
    Completion
    2015-07
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Melanoma
    InterventionAcitretin; Vemurafenib
    PhasePhase 2
    Registry statusTerminated